BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37335288)

  • 21. The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: A systematic review.
    Rowell NP
    Radiother Oncol; 2019 Jul; 136():113-120. PubMed ID: 31015112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of reoperations for medullary thyroid carcinoma.
    Fialkowski E; DeBenedetti M; Moley J
    World J Surg; 2008 May; 32(5):754-65. PubMed ID: 18188643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up.
    Barbesino G; Goldfarb M; Parangi S; Yang J; Ross DS; Daniels GH
    Thyroid; 2012 Apr; 22(4):369-76. PubMed ID: 22385290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
    Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
    Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
    Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
    Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
    [No Abstract]   [Full Text] [Related]  

  • 28. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
    Watanabe K; Igarashi T; Uchiyama M; Ojiri H
    Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiofrequency ablation for treatment of locally recurrent thyroid cancer presenting as a metastatic lymph node with dense macrocalcification: A case report and literature review.
    Yoo RE; Kim JH; Paeng JC; Park YJ
    Medicine (Baltimore); 2018 Mar; 97(9):e0003. PubMed ID: 29489641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Postoperative external beam radiotherapy for medullary thyroid carcinoma with high risk of locoregional relapse].
    Compagnon F; Zerdoud S; Rives M; Laprie A; Sarini J; Grunenwald S; Chaltiel L; Graff P
    Cancer Radiother; 2016 Jul; 20(5):362-9. PubMed ID: 27396902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medullary thyroid cancer.
    Kebebew E; Clark OH
    Curr Treat Options Oncol; 2000 Oct; 1(4):359-67. PubMed ID: 12057161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete surgical lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma.
    Franc S; Niccoli-Sire P; Cohen R; Bardet S; Maes B; Murat A; Krivitzky A; Modigliani E;
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):403-9. PubMed ID: 11589685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
    Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
    Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
    Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation.
    Yim JH; Kim WB; Kim EY; Kim WG; Kim TY; Ryu JS; Moon DH; Sung TY; Yoon JH; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3695-700. PubMed ID: 21976723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
    Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
    Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.